Yong‐Su Zhen
- Toxicology top 2%
- Bioactive Compounds and Antitumor Agents 13
- Oncology top 5%
- HER2/EGFR in Cancer Research 19
- Peptidase Inhibition and Analysis 18
- Molecular Biology top 5%
- Cancer therapeutics and mechanisms 33
- Chemical Synthesis and Analysis 22
- Biochemical and Molecular Research 12
- Cancer Research top 10%
- Physiology top 5%
-
- Monoclonal and Polyclonal Antibodies Research 33
-
- Cyclization and Aryne Chemistry 20
- Cited by
- ToxicologyOncologyMolecular Biology
- Journals
- Anti-Cancer Drugs (7 papers)Oncology Reports (6 papers)Cancer Chemotherapy and Pharmacology (6 papers)
- Partner nations
- ChinaUnited StatesUnited Kingdom
In The Last Decade
Yong‐Su Zhen
150 papers receiving 2.3k citations
Hit Papers
Peers
Comparison fields: 5 of 109
- Toxicology 100
- Oncology 658
- Molecular Biology 1.5k
- Cancer Research 255
- Physiology 66
Countries citing papers authored by Yong‐Su Zhen
This map shows the geographic impact of Yong‐Su Zhen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yong‐Su Zhen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yong‐Su Zhen more than expected).
Fields of papers citing papers by Yong‐Su Zhen
This network shows the impact of papers produced by Yong‐Su Zhen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yong‐Su Zhen. The network helps show where Yong‐Su Zhen may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Yong‐Su Zhen, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 0 | |
| 2 | 2024 | 13 | |
| 3 | 2023 | 6 | |
| 4 | 2023 | 1 | |
| 5 | Advances and challenges in the treatment of esophageal cancerbreakdown → | 2021 | 174 |
| 6 | 2021 | 95 | |
| 7 | 2020 | 6 | |
| 8 | 2019 | 12 | |
| 9 | 2018 | 25 | |
| 10 | 2018 | 22 | |
| 11 | 2016 | 3 | |
| 12 | 2016 | 37 | |
| 13 | 2015 | 20 | |
| 14 | 2014 | 9 | |
| 15 | 2013 | 19 | |
| 16 | 2010 | 38 | |
| 17 | 2008 | 9 | |
| 18 | 2005 | 14 | |
| 19 | Antitumor activity of immunoconjugates composed of boanmycin and monoclonal antibody. | 1994 | 3 |
| 20 | [Antitumor activity of bleomycin A6 against human liver cancer in cell culture and in nude mice]. | 1987 | 5 |
About Yong‐Su Zhen
Yong‐Su Zhen is a scholar working on Toxicology, Oncology and Biotechnology, having authored 154 papers that have together received 2.3k indexed citations. Recurring topics across this work include Cancer therapeutics and mechanisms (33 papers), Monoclonal and Polyclonal Antibodies Research (33 papers), Chemical Synthesis and Analysis (22 papers), Cyclization and Aryne Chemistry (20 papers), HER2/EGFR in Cancer Research (19 papers), Peptidase Inhibition and Analysis (18 papers), Bioactive Compounds and Antitumor Agents (13 papers) and Biochemical and Molecular Research (12 papers). The work is most often cited by research in Toxicology (100 citations), Oncology (658 citations) and Molecular Biology (1.5k citations). Yong‐Su Zhen has collaborated with scholars based in China, United States and United Kingdom. Frequent co-authors include Shenghua Zhang, Rong‐Guang Shao, Xiujun Liu, George Weber, Liang Li, Shiming He, Jian Xu, I. Goldberg, Shousong Cao and Yajun Lin. Their work appears in journals such as Anti-Cancer Drugs, Oncology Reports, Cancer Chemotherapy and Pharmacology, Acta Pharmacologica Sinica and Cancer Biology & Therapy.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.